Carl Firth, Aslan Pharmaceuticals CEO

Aslan touts da­ta for com­peti­tor to Dupix­ent as it seeks new part­ners

Aslan Phar­ma­ceu­ti­cals said Thurs­day morn­ing that its ex­per­i­men­tal drug for eczema, or atopic der­mati­tis, helped more pa­tients achieve near­ly clear or clear skin com­pared to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.